BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 16904890)

  • 1. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
    Charrier C; Bertrand P; Gesson JP; Roche J
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.
    Charrier C; Roche J; Gesson JP; Bertrand P
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6142-6. PubMed ID: 17897824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
    Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
    Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
    Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
    Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
    J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
    Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
    Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.
    Loudni L; Roche J; Potiron V; Clarhaut J; Bachmann C; Gesson JP; Tranoy-Opalinski I
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4819-23. PubMed ID: 17624773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
    Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
    Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
    Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
    Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
    Su H; Nebbioso A; Carafa V; Chen Y; Yang B; Altucci L; You Q
    Bioorg Med Chem; 2008 Sep; 16(17):7992-8002. PubMed ID: 18701301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.